Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

Trial Identifier: D6402C00001
Sponsor: AstraZeneca
NCTID:: NCT04595370
Start Date: January 2021
Primary Completion Date: September 2023
Study Completion Date: September 2023
Condition: Chronic Kidney Diseases; Congestive Heart Failure

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations